Rankings
▼
Calendar
RIGL Q1 2025 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RIGL
Rigel Pharmaceuticals, Inc.
$541M
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$53M
+80.6% YoY
Gross Profit
$49M
91.7% margin
Operating Income
$13M
23.9% margin
Net Income
$11M
21.5% margin
EPS (Diluted)
$0.63
QoQ Revenue Growth
-7.4%
Cash Flow
Operating Cash Flow
-$893,000
Free Cash Flow
-$893,000
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$176M
Total Liabilities
$157M
Stockholders' Equity
$19M
Cash & Equivalents
$46M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$53M
$30M
+80.6%
Gross Profit
$49M
$28M
+77.8%
Operating Income
$13M
-$7M
+283.4%
Net Income
$11M
-$8M
+238.8%
Revenue Segments
Gross product sales
$60M
60%
Product sales, net
$44M
44%
Contract revenues from collaborations
$10M
10%
Milestone
$3M
3%
Discounts and allowances
-$17M
-17%
← FY 2025
All Quarters
Q2 2025 →